

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following agents belongs to the pharmacologic class of cereblon E3 ligase modulators (CELMoDs)?
 - Mezigdomide
 - Iberdomide
 - Selinexor
 - Sonrotoclax
 - Both mezigdomide and iberdomide
 - Both selinexor and sonrotoclax
 - All of the above
- Iberdomide and mezigdomide differ from immunomodulatory drugs in which respect?
 - They only bind mutant forms of the cereblon E3 ligase
 - They bind wild-type and mutant forms of the cereblon E3 ligase
 - They are less efficient at promoting the “closed” active conformation of the cereblon E3 ligase
 - They are more efficient at promoting the “closed” active conformation of cereblon E3 ligase
- Which of the following adverse events was most commonly associated with mezigdomide in combination with dexamethasone in the Phase I study in patients with relapsed/refractory multiple myeloma (MM)?
 - Peripheral neuropathy
 - Nausea
 - Neutropenia
 - Pyrexia
- In the Phase I/II study evaluating iberdomide with dexamethasone for heavily pretreated late-line relapsed or refractory MM, the combination resulted in approximately what overall response rate?
 - 12%
 - 28%
 - 56%
 - 75%